Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

BACKGROUND: The gefitinib compassionate-use programme has enabled >39,000 patients worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of gefitinib treatment in Chinese patients who enrolled into the 'Iressa' Expanded Access Programme (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xin-Lin, Li, Long-Yun, Zhang, Xiao-Tong, Wang, Shu-Lan, Wang, Meng-Zhao
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516034/
https://www.ncbi.nlm.nih.gov/pubmed/15318946
http://dx.doi.org/10.1186/1471-2407-4-51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516034/
https://www.ncbi.nlm.nih.gov/pubmed/15318946
http://dx.doi.org/10.1186/1471-2407-4-51

Ejemplares similares